Zapping pain away: electrical acupoint therapy tested after lung surgery
NCT ID NCT07287657
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests whether adding transcutaneous electrical acupoint stimulation (TEAS) to standard pain relief can reduce pain and inflammation after lung cancer surgery. 90 people scheduled for thoracic surgery will receive either standard care alone or standard care plus TEAS. The goal is to see if this non-invasive approach improves recovery and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Transcutaneous Electrical Acupoint Stimulation (TEAS) and Transcutaneous Electrical Nerve Stimulation (TENS)
- What this could lead to
- If it works, this could offer a drug-free way to ease pain after lung surgery and reduce reliance on painkillers.
- What could go wrong
- This is a small, early-stage study with no blinding, so results may be influenced by placebo effects. The approach may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hualien Tzu Chi Hospital
Taipei, Hualien, 97002, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Could a single nerve block slash opioid use in Children's elbow surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a simple pill speed up knee replacement recovery?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success